DiaMedica Therapeutics Inc. (DMAC): Capital Expenditures
$40.0K
Year ended 2025-12-31
$33.0K
Trailing 12 months to 2026-06-30
-21.0%
3-year compound annual growth
-3.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $40.0K | +60.0% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $25.0K | +4.2% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $24.0K | -70.4% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $81.0K | +268.2% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $22.0K | -53.2% | 2023-03-28, From 2021-01-01 |
| 2020-12-31 | $47.0K | n/m | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | $2.0K | -96.0% | 2021-03-10, From 2019-01-01 |
| 2018-12-31 | $50.0K | +127.3% | 2020-03-23, From 2018-01-01 |
| 2017-12-31 | $22.0K | n/a | 2019-03-19, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $40.0K | +60.0% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $0 | -100.0% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $3.57M | +160.5% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $46.0K | -11.5% |
| Rallybio Corp (RLYB) | 2024-12-31 | $0 | -100.0% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $0 | -100.0% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $212.0K | -52.6% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $88.0K | -67.2% |
| Biomea Fusion, Inc. (BMEA) | 2024-12-31 | $362.0K | -89.3% |
Compare DMAC, QTTB, LFVN, OKUR side by side · Screen every company in Pharmaceutical Preparations ↗